A RANDOMIZED OPEN LABEL CROSS-OVER STUDY TO EVALUATE PHARMACOKINETICS AND SAFETY OF SINGLE INHALED DOSES OF ABEDITEROL AND AZD7594 GIVEN ALONE, IN FIXED DOSE COMBINATION (FDC) AND IN FREE COMBINATION, USING DPI, IN MALE HEALTHY VOLUNTEERS.
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Abediterol (Primary) ; AZD 7594 (Primary) ; Azd 7594/abediterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 11 Apr 2017 Status changed from active, no longer recruiting to completed.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.